REYON Pharmaceutical Co., Ltd.
102460.KSFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
111
Cost of Revenue
57
Gross Profit
55
Gross Margin
49.1%
Operating Income
0
Operating Margin
0.1%
Net Income
3
Net Margin
2.8%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
10
EBITDA Margin
8.6%
2023
12/31/2023
Revenue
113
Cost of Revenue
56
Gross Profit
59
Gross Margin
52.2%
Operating Income
3
Operating Margin
2.7%
Net Income
3
Net Margin
2.4%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
7
EBITDA Margin
6.0%
2022
12/31/2022
Revenue
116
Cost of Revenue
54
Gross Profit
61
Gross Margin
53.1%
Operating Income
7
Operating Margin
6.3%
Net Income
6
Net Margin
4.8%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
10
EBITDA Margin
8.8%
2021
12/31/2021
Revenue
107
Cost of Revenue
48
Gross Profit
60
Gross Margin
55.6%
Operating Income
3
Operating Margin
2.6%
Net Income
4
Net Margin
3.9%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
5
EBITDA Margin
4.3%
2020
12/31/2020
Revenue
98
Cost of Revenue
43
Gross Profit
54
Gross Margin
55.8%
Operating Income
3
Operating Margin
3.2%
Net Income
3
Net Margin
3.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
7
EBITDA Margin
7.0%